ARIX.L
Price:
$142
Market Cap:
$183.73M
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investm...[Read more]
Industry
Biotechnology
IPO Date
2017-02-17
Stock Exchange
LSE
Ticker
ARIX.L
According to Arix Bioscience plc’s latest financial reports and current stock price. The company's current PE Ratio is 12.91. This represents a change of 7.88% compared to the average of 11.97 of the last 4 quarters.
The mean historical PE Ratio of Arix Bioscience plc over the last ten years is -3.27. The current 12.91 PE Ratio has changed -39540.90% with respect to the historical average. Over the past ten years (40 quarters), ARIX.L's PE Ratio was at its highest in in the September 2022 quarter at 26.16. The PE Ratio was at its lowest in in the January 2017 quarter at 0.
Average
-3.27
Median
-0.96
Minimum
-21.40
Maximum
5.80
Discovering the peaks and valleys of Arix Bioscience plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 436.68%
Maximum Annual PE Ratio = 5.80
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -21.40
Year | PE Ratio | Change |
---|---|---|
2022 | -5.16 | 436.68% |
2021 | -0.96 | -221.85% |
2020 | 0.79 | -139.73% |
2019 | -1.99 | -134.23% |
2018 | 5.80 | -127.12% |
2017 | -21.40 | -Infinity% |
The current PE Ratio of Arix Bioscience plc (ARIX.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.78
5-year avg
-0.30
10-year avg
-3.27
Arix Bioscience plc’s PE Ratio is greater than Duke Royalty Limited (0.30), greater than NetScientific plc (-6.00), greater than Anexo Group Plc (8.71), greater than VietNam Holding Limited (5.32), less than Springfield Properties Plc (14.93),
Company | PE Ratio | Market cap |
---|---|---|
0.30 | $125.02M | |
-6.00 | $12.72M | |
8.71 | $81.41M | |
5.32 | $96.60M | |
14.93 | $112.82M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arix Bioscience plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arix Bioscience plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arix Bioscience plc's PE Ratio?
How is the PE Ratio calculated for Arix Bioscience plc (ARIX.L)?
What is the highest PE Ratio for Arix Bioscience plc (ARIX.L)?
What is the 3-year average PE Ratio for Arix Bioscience plc (ARIX.L)?
What is the 5-year average PE Ratio for Arix Bioscience plc (ARIX.L)?
How does the current PE Ratio for Arix Bioscience plc (ARIX.L) compare to its historical average?